C
MYGN icon

Covestor’s Myriad Genetics MYGN Stock Holding History

Covestor’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
85
+75
+750% +$340 ﹤0.01% 2713
2026
Q1 		$0 Hold
10
– – ﹤0.01% 2592
2025
Q4 		$0 Sell
10
-1
-9% -$7 ﹤0.01% 2567
2025
Q3 		$0 Sell
11
-55
-83% -$327 ﹤0.01% 2578
2025
Q2 		$0 Sell
66
-17
-20% -$100 ﹤0.01% 2545
2025
Q1 		$1K Buy
83
+38
+84% +$456 ﹤0.01% 2042
2024
Q4 		$1K Buy
45
+39
+650% +$720 ﹤0.01% 2084
2024
Q3 		$0 Hold
6
– – ﹤0.01% 2545
2024
Q2 		$0 Hold
6
– – ﹤0.01% 2560
2024
Q1 		$0 Hold
6
– – ﹤0.01% 2556
2023
Q4 		$0 Sell
6
-5
-45% -$86 ﹤0.01% 2496
2023
Q3 		$0 Sell
11
-4
-27% -$76 ﹤0.01% 2480
2023
Q2 		$0 Sell
15
-3
-17% -$65 ﹤0.01% 2460
2023
Q1 		$0 Sell
18
-3
-14% -$61 ﹤0.01% 2381
2022
Q4 		$0 Buy
21
+2
+11% +$37 ﹤0.01% 2402
2022
Q3 		$0 Buy
19
+8
+73% +$184 ﹤0.01% 2373
2022
Q2 		$0 Sell
11
-3
-21% -$62 ﹤0.01% 2191
2022
Q1 		$0 Sell
14
-3
-18% -$77 ﹤0.01% 2310
2021
Q4 		$0 Buy
+17
New +$493 ﹤0.01% 2226

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Covestor's MYGN Position: Q2 2026 in Review

Covestor increased its Myriad Genetics (MYGN) stake by 750% in Q2 2026, buying an estimated $340 and bringing the position to 85 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2713.

Covestor first reported a position in MYGN in Q4 2021 and has held it in 19 quarters since. The position peaked at $1K in Q1 2025. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Covestor held 85 shares of Myriad Genetics worth $0 as of Q2 2026.
  • Covestor bought 75 Myriad Genetics shares in Q2 2026, an estimated $340.
  • Myriad Genetics made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2713 holding.
  • Covestor first reported a position in Myriad Genetics in Q4 2021 and has held it in 19 quarters since.
  • Covestor's Myriad Genetics position peaked at $1K in Q1 2025.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.